The Addario Lung Cancer Medical Institute (ALCMI) is a 501(c)(3) non-profit, public charity organization, with offices in California and Connecticut and member institutions in the US and Europe, dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. In response to widely-acknowledged and systematic barriers to progress against lung cancer, ALCMI developed and launched, as its inaugural research program, a targeted, multi-institutional biorepository. The purpose of this project is to facilitate application of the known biomarkers to patients presenting today, and to establish such a collection of biospecimens that will be essential for discovering and validating new biomarkers for improved diagnostics, treatments and cancer patient outcomes.

ALCMI is a participating member of FasterCures' TRAIN (The Research Acceleration and Innovation Network) which was established to identify and promote models of innovation and collaboration in medical research. FasterCures has created TRAIN and connected dozens of disease research organizations with results–oriented research methods; thus amplifying best practices and telling the story of “entrepreneurs for cures” to bring sense of urgency to the rest of the medical research community.